Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"MARK2 pseudogene 3" (MARK2P3) is a genomic DNA sequence sharing significant homology with the protein-coding MARK2 gene but lacks the capacity to encode a functional protein due to mutations or incomplete structure[3][5]. Pseudogenes such as MARK2P3 typically arise from gene duplication or retrotransposition events. While most pseudogenes were traditionally regarded as nonfunctional, some have been shown to exert regulatory effects at the RNA level—acting as competitive endogenous RNAs (ceRNAs) or antisense regulators in specific biological contexts[4]. However, there is no literature or database evidence indicating that MARK2P3 has any unique or established function, druggability, or role as a biomarker or therapeutic target. It should not be confused with the functional gene MARK2, a serine/threonine kinase involved in cell polarity and microtubule dynamics[1]. In summary, MARK2P3 is a pseudogene and not a validated molecular target of interest for drug discovery, therapeutic intervention, or biomarker development as of current knowledge.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MARK2 pseudogene 3 (MARK2P3).